DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20201816

Use of vaginal misoprostol before endometrial biopsy in premenopausal women: an observational study

Prabhavathi V., Prasad D. K. V., Lahari N., Satyavathi R.

Abstract


Background: It is well-known since long time the beneficial effects of misoprostol particularly as a cervical softening agent in obstetric practice. Keep in view, study aimed to evaluate the efficacy of vaginal misoprostol 400 mcg before endometrial biopsy in premenopausal women.

Methods: All the 200 patients were classified into two groups viz. study group (Group I) with 100 patients and control group (Group II) with 100 patients. To Group I patients, 400 mcg of misoprostol was given vaginally, 4 hours prior to the commencement of endometrial biopsy whereas no medication was received by Group II patients.

Results: In the present study, the base line cervical dilatation is found to be 5.8±1.3 mm in Group I patients whereas 3.8±0.92 mm in Group II patients which is significantly higher (p<0.05). Only 32 patients in Group I required further dilatation whereas 88 patients in Group II underwent further dilatation. The mean time required for further dilatation in Group I and Group II patients was 42.6±17.4, 64.6±16.8 sec respectively and was significantly higher in Group II patients (p<0.05). Out of 100 patients in Group I, only 2% of patients complained severe pain whereas in Group II 48% of patients experienced intolerable pain and required anesthesia.

Conclusions: Vaginal administration of 400 mcg misoprostol 4 hours prior to endometrial biopsy in premenopausal women had a significant effect on cervical resistance and cervical dilatation.


Keywords


Cervical injury, Cervical ripening, Endometrial biopsy, Prostaglandin E1, Visual analog scale score

Full Text:

PDF

References


Bradley LD. Overview of hysteroscopy Version 17.2. Available at: http://www.uptodate.com. Accessed on 14th September 2009.

Cooper JM, Erickson ML. Endometrial sampling techniques in the diagnosis of abnormal uterine bleeding. Obstet Gynecol Clin North Am. 2000;27:235-44.

Hofmeyr GJ, Gülmezoglu AM, Alfirevic Z. Misoprostol for induction of labour: A systematic review. Br J Obstet Gynaecol. 1999;106:798-803.

Cecatti JG, Tedesco RP, Pires HM, Calderon IM, Faúndes A. Effectiveness and safety of a new vaginal misoprostol product specifically labeled for cervical ripening and labor induction. Acta Obstet Gynecol Scand. 2006;85:706-11.

Sahu L, Chakravertty B. Comparison of prostaglandin E 1 (misoprostol) with prostaglandin E 2 (dinoprostone) for labor induction. J Obstet Gynecol India. 2004;54:139-42.

Sakhare AP, Mahale AR, Kardile GP. Vaginal misoprostol for medical evacuation of missed abortion. J Obstet Gynecol India. 2005;55:178-9.

Hamoda H, Ashok PW, Flett GM, Templeton A. A randomized controlled comparison of sublingual and vaginal administration of misoprostol for cervical priming before first-trimester surgical abortion. Am J Obstet Gynecol. 2004;190:55-9.

Blanchard K, Clark S, Winikoff B, Gaines G, Kabani G, Shannon C. Misoprostol for women’s health: a review. Obstet Gynecol. 2002;99:316-32.

Carbonell JL, Velazco A, Rodriguez Y, Tanda R, Sanchez C, Barambio S, et al. Oral versus vaginal misoprostol for cervical priming in first-trimester abortion: a randomized trial. Eur J Contracept Reprod Health Care. 2001;6: 134-140.

MacIsaac L, Grossman D, Balistreri E, Darney P. A randomized controlled trial of laminaria, oral misoprostol, and vaginal misoprostol before abortion. Obstet Gynecol. 1999;93:766-70.

Tenore JL. Methods for cervical ripening and induction of labor. Am Fam Physician. 2003;67:2123-8.

Briggs GG, Wan SR. Drug therapy during labor and delivery, part 2. Am J Health Syst Pharm. 2006;63:1131-9.

Crane JM, Healey S. Use of misoprostol before hysteroscopy: a systematic review. J Obstet Gynaecol Can. 2006;28:373-9.

Oppegaard KS, Nesheim BI, Istre O, Qvigstad E. Comparison of self administered vaginal misoprostol versus placebo for cervical ripening prior to operative hysteroscopy using a sequential trial design. BJOG. 2008;115:663,e1-9.

Lee YY, Kim TJ, Kang H, Choi CH, Lee JW, Kim BG, et al. The use of misoprostol before hysteroscopic surgery in non-pregnant premenopausal women: A randomized comparison of sublingual, oral and vaginal administrations. Hum Reprod. 2010;25:1942-8.

Dan Yu, Li TC, Xia E, Xiaowu H. A prospective randomized controlled trial comparing vaginal misoprostol and osmotic dilator in achieving cervical ripening before operative hysteroscopy. Gynecol Surg. 2006;3:186-9.

Perrone JF, Caldito G, Mailhes JB, Tucker AN, Ford WR, London SN. Oral misoprostol before office endometrial biopsy. Obstet Gynecol. 2002;99:439-44.

Fung TM, Lam MH, Wong SF, Ho LC. A randomised placebo-controlled trial of vaginal misoprostol for cervical priming before hysteroscopy in postmenopausal women. BJOG. 2002;109:561-5.

Khan RU, El-Refaey H, Sharma S, Sooranna D, Stafford M. Oral, rectal, and vaginal pharmacokinetics of misoprostol. Obstet Gynecol. 2004;103:866-70.

Batukan C, Ozgun MT, Ozcelik B, Aygen E, Sahin Y, Turkyilmaz C. Cervical ripening before operative hysteroscopy in premenopausal women: a randomized, double-blind, placebo-controlled comparison of vaginal and oral misoprostol. Fertil Steril. 2008;89:966-73.

Choksuchat C, Cheewadhanaraks S, Getpook C, Wootipoom V, Dhanavoravibul K. Misoprostol for cervical ripening in non-pregnant women: a randomized double-blind controlled trial of oral versus vaginal regimens. Hum Reprod. 2006;21:2167-70.

Carbonell Esteve JL, Mari JM, Valero F, Llorente M, Salvador I, Varela L, et al. Sublingual versus vaginal misoprostol (400 microg) for cervical priming in first-trimester abortion: a randomized trial. Contracept. 2006;74:328-33.